Prothena Corporation plc To Be Added To Nasdaq Biotechnology Index And Nasdaq Global Select Market
Published: Dec 30, 2013
DUBLIN, Ireland, Dec. 30, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it was selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), which became effective before market open on December 23, 2013. Prothena also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014.
Help employers find you! Check out all the jobs and post your resume.